Stakeholders commenting on the US Food and Drug Administration’s draft guidance on registration and listing requirements under the Modernization of Cosmetics Regulations Act (MoCRA) will urge the agency to use enforcement discretion as concerns grow over the approaching year-end deadline.
Two attorneys who spoke with HBW Insight on 10 August, three days after the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?